Skip to main content
. Author manuscript; available in PMC: 2021 Oct 25.
Published in final edited form as: Cancer Res. 2012 Jan 26;72(6):1384–1394. doi: 10.1158/0008-5472.CAN-11-2905

Figure 4. Versican enhances proliferation and induces MET in metastatic tumor cells.

Figure 4.

A, Flow cytometry plots depicting cell cycle analysis of metastatic breast cancer MDA-MB-231 cells treated with Gr1+ CM or control media (Cont). Percentage of S phase cells are indicated. Representative plots are from 3 experiments.

B, Quantitative RT-PCR analysis of epithelial/mesenchymal marker expression in MDA-MB-231 cells treated with Gr1 CM, or biochemically purified versican (+Vcn, 2.5 μg/mL). n=3, *p<0.01 as compared to untreated cells (Cont).

C, Microscopy images of MDA-control cells and MDA-versican cells (MDA-Vcn) depicting morphology (Phase) and expression of epithelial/mesenchymal markers. E-cad,E-cadherin; Vim,vimentin.

D, Western blot analysis of versican (>250 KDa), EMT markers, phospho (p)-Smad2, and total Smad2/3 expression in MDA (Vcn) cells and MDA (Cont) cells. Representative data from three experiments.

HHS Vulnerability Disclosure